BUZZ-Exact Sciences climbs as FDA approves its new colorectal cancer test
Shares of cancer test maker Exact Sciencesrise ~1.2% to $67.22 premarketCompany says U.S. FDA approved its stool DNA test called “Cologuard Plus” to screen for colorectal cancerEXAS says the new test will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening testColorectal cancer develops in the colon or rectum, which are parts of the large intestineUp to last close, stock down 10.2% YTD
Shares of cancer test maker Exact Sciences (EXAS.O) rise ~1.2% to $67.22 premarket
Company says U.S. FDA approved its stool DNA test called “Cologuard Plus” to screen for colorectal cancer
EXAS says the new test will minimize unnecessary follow-up colonoscopies by reducing the likelihood of a false-positive screening test
Colorectal cancer develops in the colon or rectum, which are parts of the large intestine
Up to last close, stock down 10.2% YTD
